Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Shareholder Meeting (April 2021)
19 slides from Sona Nanotech's shareholder meeting presentation, April 2021
Slide 1: Unique Nanoparticle Technology for Rapid Diagnostics and 'In Vivo' Applications
UNIQUE NANOPARTICLE TECHNOLOGY FOR RAPID DIAGNOSTICS AND ‘IN VIVO’ APPLICATIONS WWW.SONANANO.COM CSE:SONA | OTC:SNANF April 2021 1
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and
Slide 3: Company Highlights
COMPANY HIGHLIGHTS Patent pending GNR platform technology without CTAB positions Sona to potentially disrupt the $26B1 global point-of-care diagnostic market Lead product is a 20-minute, easy to use, antigen lateral flow saliva test that screens for COVID-19 currently in clinical trial and the Compa
Slide 4: Sona at a Glance
SONA AT A GLANCE Sona Nanotech is a nanotechnology life sciences company that has developed multiple proprietary methods for the manufacture of gold nanorods (GNR’s) Nanotechnology: the use of matter on an atomic, molecular, and supramolecular scale Gold Nanorods: gold nanoparticles that are elongat
Slide 5: Sona's GNR Technology in LFA's
SONA’S GNR TECHNOLOGY IN LFA’S Lateral Flow Assays (LFA’s) are simple, fast, and low-cost Point of Care (PoC) diagnostic or screening tools which can provide rapid results (i.e. at-home pregnancy tests). Sona applies its proprietary GNR technology without CTAB in LFA’s with a view to increasing sens
Slide 6: The Global Rapid Diagnostic Market
THE GLOBAL RAPID DIAGNOSTIC MARKET Rapid Diagnostic Tests (RDT’s) are medical screening or diagnostic tests that 2027 are mobile, quick and easy to perform, and provide rapid results. $55.4B The global PoC diagnostics market is expected to grow to USD $55.4 Billion with 9.6% CAGR over the next six y
Slide 7: Why COVID-19 Rapid Testing Still Matters
WHY COVID-19 RAPID TESTING STILL MATTERS • Not all will get vaccinated - some can’t or won’t vaccinate • No vaccine is guaranteed 100% - especially with mutations • Need to identify outbreaks – early detection key to minimizing spread • Vaccine may not stop transmission – virus can still be spread b
Slide 8: NP Swabs: The More Often Used, The Less Liked
NP SWABS: THE MORE OFTEN USED, THE LESS LIKED Current rapid tests typically rely upon invasive, nasopharyngeal (NP) swabs SONANANO. CSE:SONA | OTC:SNANF 8 COM
Slide 9: Sona's Saliva Test: More Comfortable and Safer to Administer
SONA’S SALIVA TEST: MORE COMFORTABLE AND SAFER TO ADMINISTER Rest it in the mouth and leave until vial turns blue SONANANO. CSE:SONA | OTC:SNANF 9 COM
Slide 10: A Saliva-Based Test: Version 2.0 of Sona's Rapid COVID-19 Antigen Test
A SALIVA-BASED TEST: VERSION 2.0 OF SONA’S RAPID COVID-19 ANTIGEN TEST Sona has developed a prototype for a second generation of its rapid COVID-19 antigen test that uses saliva instead of nasal pharyngeal samples Benefits: • Less invasive sample collection means safer and simpler sample collection
Slide 11: Sona's Saliva Test Validation Path
SONA’S SALIVA TEST VALIDATION PATH Conducted Robustness Robustness Europe first and then Sona to consider with gamma and flex studies and flex studies North America partnerships irradiated virus IN-HOUSE THIRD PARTY REGULATORY MANUFACTURING COMMERCIALIZATION VALIDATION VALIDATION TECHNOLOGY TRANSFER
Slide 12: Sona Beyond COVID-19
SONA BEYOND COVID-19 Three Streams of Focus #3. Higher-value GNR Applications #2. Consumer Health • Enhancing GNR capabilities LFA Offerings #1. Near-term POC • Explore ‘in vivo’ GNR applications • Scoping products • Create Sona GNR awareness LFA Applications • Get referenced in published • Explore
Slide 13: Future Rapid Test Development Screen
FUTURE RAPID TEST DEVELOPMENT SCREEN Currently Requires Selected Considerations: Subjective Periodic Testing Assessment ● Commercial ○ Market size Irritable *Iron ○ Competitors Bowel Syndrome Concussion, *CVD ● Regulatory hurdles (IBS) *Prostate Celiac Etc. *Vitamin D ● Economics Sepsis *Strep Throa
Slide 14: Second Commercialization: Concussion Screening Test
SECOND COMMERCIALIZATION: CONCUSSION SCREENING TEST Sona is applying its GNR technology to develop a rapid concussion screening test. The test is intended to detect the presence of GFAP (Glial Fibrillary Acidic Protein), a biological marker associated with concussions, typically released into the bl
Slide 15: Concussion Rapid Test Background
CONCUSSION RAPID TEST BACKGROUND Concussion Biomarkers • Prototype is designed to detect Glial Fibrillary Acidic Protein (GFAP) which is the initial marker produced indicating damage to the brain. • GFAP levels spike within minutes of a concussion and remain at significant levels for several hours.
Slide 16: Longer Term Applications
LONGER TERM APPLICATIONS Because they are CTAB-free and therefore bio-friendly, Sona's gold nanorods may be ideal for ‘in-vivo’ applications in which they are used for tracking and targeting with the long-term potential for profound health benefit implications. IN-VITRO IN-VIVO Diagnostics / Detecti
Slide 17: Gold Nanorod Photothermal Ablation
GOLD NANOROD PHOTOTHERMAL ABLATION Tumor Ablation Example(1) • A 3rd party study using GNR’s eliminated tumors in mice in 4 weeks(1) • GNR’s injected in tumors and heated with near-IR laser • Key issue: • While using gold ‘in vivo’ is understood to be safe, the long-term effects of GNRs treated with
Slide 18: Stock Information
STOCK INFORMATION CSE:SONA | OTC:SNANF approvals. MARKET CAPITALIZATION Shares Outstanding - basic: 64M Diluted for ‘in-the-money’ options and warrants: 67M Insider Ownership: 13.2% Market Capitalization: CAD $115M Six Month High and Low: $5.38/$0.78 Previous Quarter 608,020 Average Daily Volume: *
Slide 19: Contact
CONTACT WWW.SONANANO.COM | +1-902-442-0653 1969 Upper Water Street Suite 2001, Purdy’s Tower II Halifax, Nova Scotia, Canada B3J 3R7 KIN COMMUNICATIONS Investor Relations +1 604-684-6730 [email protected] SONANANO. CSE:SONA | OTC:SNANF 19 COM